First-Line Treatment of Acute Adult T-Cell Leukemia-Lymphoma Without Bulky Lesions
The acute subtype of adult T-cell leukemia-lymphoma (ATLL) presenting without bulky lesions and without lymphoma-type features represents a distinct clinical scenario. Recognising this subgroup is essential, as it directs a specific first-line therapeutic strategy that differs from other ATLL subtypes.
Clinical Scenario
Acute adult T-cell leukaemia-lymphoma; without bulky lesions; non-lymphoma type. The combination of acute-type disease, absence of bulk, and non-lymphomatous presentation defines this population and informs treatment selection.
Treatment Approach (Overview)
First-line treatment for this subgroup involves zidovudine combined with interferon-α. The regimen is accompanied by central nervous system prophylaxis for all patients, as well as antimicrobial prophylaxis against opportunistic infections.
Full dosing guidance, sequencing, prophylaxis protocols, and eligibility criteria are available in the complete structured regimen.
Treatment Goal
The clinical objective is to achieve chemosensitive disease in response to first-line therapy, enabling consolidation.
References
DOI: 10.1016/j.annonc.2025.01.023
- High-dose zidovudine-IFN-a can be recommended as first-line therapy for patients with acute, non-bulky, non-lymphomatous ATLL whenever feasible, particularly for those who are unsuitable for intensive ChT or allo-HSCT [III, B; not EMA or FDA approved].
- CNS prophylaxis can be recommended for all patients with acute or lymphoma-type ATLL [III, B].
- Antimicrobial prophylaxis for opportunistic infections can be recommended for all patients [II, B].
- In case of positive Strongyloides stercoralis serology, treatment can be initiated even if the patient is asymptomatic [III, B].
View source ↗